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Abstract
Background
There is increasing evidence that postprandial hyperglycaemia is implicated in the development of macro- and microvascu-
lar diabetic complications. Thus, control of postprandial glucose levels (PPG), in addition to control of fasting blood glucose 
(FBG), will ensure overall glycaemic control in diabetic patients. This study evaluated the effectiveness of a current anti-dia-
betic regimen on PPG in patients with type 2 diabetes mellitus.
Method
A total of 31 type 2 diabetic subjects on combination treatment of either Humulin N® (HN), Monotard HM (ge)® (M) or Humulin 
L® (HL) insulin, with metformin, participated in a controlled, prospective, one-day visit study at a tertiary referral state diabetes 
clinic. The objective was to evaluate the effectiveness of the combination treatment of either M (n = 11) versus HN (n = 10) or 
HL (n = 10) insulin, each in combination with metformin, on PPG in this study cohort. Each subject was given a standardised 
meal after completing baseline procedures. Prescribed insulin doses were taken the night prior to the study day and met-
formin doses were taken with the standardised meal on the following morning, the study day. After completion of the meal, 
blood glucose levels were determined every half an hour at 0, 30, 60, 90, 120 and 150 minutes, thus providing a postprandial 
glucose profile for each subject. The data was analysed using ANOVA. 
Results
The study cohort was South African, predominantly of Indian origin (54.8%), with a mean age of  59.2 ± 8 years, and 71% of 
the cohort was female. The subjects had a mean duration of diabetes of 11.4 ± 6.6 years, with 71% (n = 22) having a positive 
family history. The study cohort was obese (BMI 32.3 ± 6.2kg/m2, WHR 0.9 ± 0.1). A total of 61.3% (n = 19) of the study cohort 
was hypertensive, while 29% (n = 9) presented with at least one cardiovascular event and 48.3% (n = 15) had high total cho-
lesterol. On entry to the study, the mean (± SD) FBG (10.3 ± 3.7mmol/l), fructosamine (369.9 ± 78.8mol/l) and glycosylated 
haemoglobin (9 ± 2%) were elevated. Each insulin group, HN, M and HL, was statistically matched for the above-mentioned 
and was therefore compared. 
There was no statistically significant difference in the effectiveness of HN, M and HL, each in combination with metformin, 
on postprandial glucose levels (AUC glucose 0-150 minutes was 2100, 2212.5 and 2362.5mmol.min.l-1, per group respec-
tively). Each insulin group presented with mean postprandial hyperglycaemia (PPH) at all time intervals (30, 60, 90, 120 and 
150 minutes). Peak glucose levels were observed at 90 (16mmol/l), 90 (16.9mmol/l) and 60 minutes (17.6mmol/l) for HN, M 
and HL groups respectively. Since there was no statistically significant difference in PPH between and amongst the insulin 
groups at 60, 90 and 120 minutes, an approximation of PPG at 60 minutes would not adversely affect the determination of 
PPG compared to the recommended two hours. Within the HN, M and HL groups, a statistically significant difference in blood 
glucose levels was observed at 0 and 120 minutes (p = 0.003, 0.009 and 0.019 respectively). Groups with a higher FBG 
(at 0 minutes) had higher PPG (at 120 minutes), thus showing that the extent of FBG determines the degree of postprandial 
glycaemia. 
Conclusion
In this study, HN, M and HL, each in combination with metformin, were not effective in controlling postprandial hypergly-
caemia. HN was most effective in lowering the postprandial profile, although this was not statistically significant. The current 
treatment of the study cohort was also reviewed, as both FBG and PPG were not controlled. The use of a combination of 
short/rapid-acting insulin with a newly- formulated basal insulin is recommended, as both FBG and PPG should be treated to 
achieve overall glycaemic control. 
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Introduction
Diabetes mellitus (DM) is a rapidly 
growing metabolic disorder of multiple 
aetiology. It is classified according to 
the American Diabetes Association 
(ADA) and World Health Organisation 
(WHO) into four aetiological categories, 
viz. type 1, type 2, diabetes due to other 
specific mechanisms or conditions, and 
gestational diabetes.1 
Type 2 diabetes is one of the most 
common metabolic disorders and is 
now regarded as a worldwide epidemic, 
accounting for approximately 90% of all 
cases of diabetes.2
Type 2 DM is characterised by rela-
tive insulin deficiency and impaired in-
sulin action. It generally forms part of the 
‘metabolic syndrome,’ which comprises 
insulin resistance, obesity and a range 
of cardiovascular risk factors, such as 
dyslipidaemia and hypertension. Type 2 
DM therefore poses a major therapeutic 
challenge, as it is involved in the patho-
genesis of the specific macro- (cardio-
vascular events) and microvascular (ne-
phropathy, retinopathy and neuropathy) 
complications of diabetes mellitus.3 
The UK Prospective Diabetes Study 
(UKPDS 37) recently demonstrated that 
tight blood glucose control decreases 
the risk of micro- and macrovascular 
complications of DM.4 Current mea-
sures of glycaemic control include FBG, 
glycosylated haemoglobin (HbA1c) and 
fructosamine.
In type 2 DM, FBG is the main param-
eter of glucose metabolism that is used 
to monitor and control hyperglycaemia.5 
FBG informs the clinician of the patient’s 
glycaemic status relative to the time at 
which the test was done. But it gives no 
indication of glucose exposure, toxicity 
or organ damage. HbA1c, which is the 
gold standard in accessing glycaemic 
control, and fructosamine are both indi-
ces of long-term blood glucose control, 
as they estimate blood glucose during 
the preceding three months and two to 
three weeks respectively.5 
However, it is estimated that 40 to 
50% of individuals with type 2 diabetes 
are unaware that they have the disease, 
and that it may be undiagnosed for five 
to 10 years prior to clinical recognition.6 
Thus, recently-updated diagnostic cri-
teria for diabetes have included tighter 
and more specific diagnostic tools, such 
as PPG. According to the WHO, PPH re-
fers to blood glucose levels exceeding 
11.1mmol/L two hours after a meal.7
PPH is an independent risk indicator for 
micro- and macrovascular complica-
tions, not only in type 2 DM, but also in 
those with impaired glucose tolerance.8 
Several studies, such as the Helsinki 
Policeman Study,9 the Honolulu Heart 
Program10 and the Islington Diabetes 
Survey,11 have demonstrated a direct 
relationship between postprandial hy-
perglycaemia and cardiovascular com-
plications. PPH is implicated in the 
development of cardiovascular disease 
through its harmful effects on the vas-
culature, carotid artery sclerosis and 
enhanced lipid peroxidation.12 
The National Health and Nutrition 
Examination Survey found that patients 
who had PPH experienced a threefold 
increase in retinopathy, despite hav-
ing normal fasting glucose levels.13 
Repeated exposure to postprandial 
hyperglycaemia can lead to β-cell dys-
function, which may become irreversible 
over time. This glucose toxicity induces 
a gradual, time-dependent establish-
ment of irreversible damage to cellular 
components of insulin production and, 
therefore, to insulin content and secre-
tion.14 
The prevention and management of 
the complications of diabetes should 
therefore target both chronic and acute 
glucose fluctuations. While current dia-
betes treatment is focused on targeting 
FBG, the WHO and ADA recently includ-
ed PPG in the metabolic assessment of 
type 2 DM.7 
Objectives
The aim of this study was to evaluate 
postprandial glucose excursions in type 
2 diabetes mellitus patients on M versus 
HL or HN insulin, each in combination 
with metformin. The primary objective 
of this study was to determine if the cur-
rent anti-diabetic treatment of the study 
cohort controlled postprandial glucose 
levels. 
Methods
All subjects were recruited from the Dia-
betes Unit at Addington Hospital, Kwa-
Zulu-Natal. Thirty-one type 2 diabetic 
subjects were selected, based primarily 
on the metformin and basal insulin treat-
ment used. 
Subjects were grouped according to 
the basal insulin taken, i.e. HN (n = 10), 
M (n = 11) or HL (n = 10) insulin, each in 
combination with metformin. Insulin can 
be categorised into four principal types, 
namely short-acting, intermediate, long-
acting and biphasic insulins, all of which 
are similar in their pharmacodynamic 
profiles, but differ in their pharmacoki-
netics. The insulins HN, M and HL, used 
in this study, belong to the intermediate 
basal insulin category. Intermediate 
insulin is divided into lente and NPH 
(neutral protamine hagedon) insulin, 
which have zinc and protamine ions 
respectively, and which are responsible 
for delaying absorption and extending 
the duration of action. HL and M are 
lente insulins (duration of action is 22 to 
24 hours), whilst HN is an NPH insulin 
(duration of action is 18 to 24 hours).15 
This controlled, prospective study 
required a one-day visit per subject. 
On the study day, the subjects were 
required to come to the clinic fasting. 
The subjects continued with their con-
current medication and were required 
to maintain their current drug regimens 
by taking the insulin (HN, M or HL) dose 
at bedtime and the metformin doses, 
in divided doses, as prescribed. The 
baseline determinations included blood 
pressure readings and weight, height, 
hip and waist measurements. Blood 
samples were collected for biochemical 
measures: full blood count (FBC), urea 
and electrolytes (U&E), lipid profile, liver 
function tests (LFT) and glycaemic mea-
sures (fructosamine, HbA1c and FBG 
values). 
Figure 1: Illustration of the timeline of the study
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Prescribed insulin doses were taken the 
night prior to the study day and met-
formin doses were taken with the stan-
dardised meal the following morning, 
on the study day. Subjects consumed 
a standardised meal (carbohydrate 
content of 55.9 g, protein of 13.6 g and 
fat of 12.4 g) to completion over a 15-
minute period in the presence of the 
researcher. 
After completion of the meal, blood 
glucose levels were determined within 
the allocated time (using the glucose 
oxidase method) every half an hour at 
0, 30, 60, 90, 120 and 150 minutes, thus 
providing a postprandial glucose profile 
for each subject (see Figure 1). 
The data was analysed using ANO-
VA. The null hypothesis for this study 
states that there is no difference in the 
means of the three groups for a specific 
parameter. If the p value is > 0.05, the 
null hypothesis is accepted. All data 
are reported as means [± standard de-
viation (SD)] and statistical significance 
was defined as p < 0.05. 
Results
The study cohort was South African, 
predominantly of Indian origin (54.8%), 
was aged 59.2 ± 8 years and 71% were 
females. The subjects had a mean dura-
tion of diabetes of 11.4 ± 6.6 years, with 
71% (n = 22) having a positive family 
history. 
The study cohort was obese (body 
mass index (BMI) 32.3 ± 6.2kg/m2, 
waist-hip ratio (WHR) 0.9 ± 0.1). A total 
of 61.3% (n = 19) of the study cohort 
were hypertensive, while 29% (n = 9) 
presented with at least one cardiovas-
cular event and 48.3% (n = 15) had high 
total cholesterol. Drug history included 
32.3% (n = 10) on ACE inhibitors, 32.3% 
(n = 10) on low-dose diuretics, 29% (n 
= 9) on calcium antagonists, 19.4% (n 
= 6) were on β-blockers, and 0% (n = 
0) on cholesterol-lowering drugs. The 
mean FBC, U&E and LFT for the study 
population were within the normal labo-
ratory range, except for globulin levels, 
which were elevated in 90% (n = 28) of 
the study population. 
Each insulin group, HN, M and HL, 
was statistically matched for param-
eters, as per Table I. It was therefore 
possible to make comparisons between 
and among the groups.
PARAMETER  
HN   




(n = 10) 
p VALUE*
Age (years) 57.6 ± 6.5 59.2 ± 10.7 60.7 ± 6.3 0.703
Duration of DM (years) 12.3 ± 8.3 11.6 ± 5.9 10.3 ± 5.9 0.796
Total daily insulin 
dose (iu) 
36.1 ± 17.7 37.6 ± 14.3 34.5 ± 11.9 0.89
Total daily metformin 
dose (mg) 
1710 ± 443 1886 ± 661.1 1920 ± 542.2 0.67
HDL:LDL ratio 0.34 ± 0.09 0.31 ± 0.07 0.28 ± 0.1 0.341
Urea (mmol/L) 4.9 ± 1.9 5.7 ± 2.3 4.6 ± 1.9 0.417
Creatinine (µmol/L) 73.9 ± 10.8 97.7 ± 30.9 100 ± 40.5 0.113
FBG (mmol/L) 9.2 ± 2.08 10.5 ± 4.7 11.5 ± 4.2 0.430
Fructosamine (µmol/L) 371.5 ± 78.8 360.4 ± 79.9 378.7 ± 84.8 0.873
HbA1c (%) 8.3 ± 1.5 9 ± 2.1 9.8 ± 2.2 0.296
Table I: Comparison of mean ± SD of parameters for Humulin N® (HN), Monotard (M) ® and 
Humulin L® (HL) groups
*p values > 0.05 indicate no differences between group means
The mean +/- SD blood glucose level at each time point (see table 2) was above the recom-
mened 11.1 mmol/l, indicating that the study cohort had postprandial hyperglycaemia’
On closer inspection (see Table III), 
HN showed the largest, but not statisti-
cally significant, decrease in postpran-
dial glucose levels (lowest AUC glucose 
0-150 minutes). 
*Peak glucose levels were observed 
at 90 (16 mmol/L), 90 (16.9 mmol/L) and 
60 minutes (17.6 mmol/L) for the HN, M 
and HL groups respectively. Since there 
was no statistically significant difference 
in PPH between and among the insulin 
groups at 60, 90 and 120 minutes, an 
approximation of PPG at 60 minutes 
would not adversely affect the determi-
nation of PPG, compared to the recom-
mended two hours. This is of particular 
importance in busy clinical settings. 
Within the HN, M and HL groups, 
a statistically significant difference in 
blood glucose levels was observed at 
0 and 120 minutes (p = 0.003, 0.009 
and 0.019 respectively). The HN, M and 
HL groups presented with mean fasting 
hyperglycaemia at 0 minutes of 9.1 ± 
2.2, 9.3 ± 3.7 and 11.5 ± 3.6 mmol/L 
respectively and a mean postprandial 
hyperglycaemia at 120 minutes of 15.3 
± 3.7; 15.7 ± 4.1 and 16.3 ± 4.7 mmol/L 
respectively. Groups with a higher FBG 
(at 0 minutes) presented with higher 
PPG (at 120 minutes), thus indicating 
that the extent of FBG determines the 
degree of postprandial glycaemia. 
Discussion and conclusion 
In this study, ADA and WHO criteria 
were used to define fasting hypergly-
caemia as blood glucose levels ≥ 7 
PARAMETER (mmol/L) HN M HL p VALUE*
Ave FBG at 0 min 9.1 ± 2.2 9.3 ± 3.7 11.5 ± 3.6 0.200
Ave PPG at 30 min 13.3 ± 2.5 14.9 ± 3.3 16.2 ± 4.3 0.171
Ave PPG at 60 min 15.5 ± 3.6 16.8 ± 3 17.6 ± 4.7 0.471
Ave PPG at 90 min 16 ± 4 16.9 ± 3.7 17.6 ± 4.2 0.674
Ave PPG at 120 min 15.3 ± 3.7 15.7 ± 4.1 16.3 ± 4.7 0.869
Ave PPG at 150 min 14 ± 3.6 14.1 ± 4.2 14.8 ± 4.7 0.898
Table II: Comparison of mean (± SD) blood glucose profiles between insulin groups
*p values > 0.05 indicate no differences between group means
There was no statistically significant difference in the effectiveness of HN, M and HL, each in 










HN 330 750 1207.5 1665 2100
M 360 817.5 1305 1777.5 2212.5
HL 397.5 892.5 1410 1905 2362.5
p Values* 0.198 0.376 0.378 0.231 0.264
Table III: Change of mean glucose area under the curve per time interval per insulin group
 p values > 0.05 indicate no differences between insulin groups per time interval
This decrease in postprandial glucose level was followed by M and then HL, which showed the 
smallest reduction (highest AUC values)’
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mmol/L, and the WHO criteria were 
used to define two-hour postprandial 
hyperglycaemia as blood glucose levels 
≥ 11.1 mmol/L after a meal.7
The high mean ± SD FBG, HbA1c 
and fructosamine levels of the total 
study cohort showed the poor status of 
glycaemic control in the subjects, not 
only on entry into the study, but also 
over the previous months. As glycaemic 
measures were high on entry, the study 
cohort was already at a high risk for dia-
betic complications. 
The mean age, duration and posi-
tive history of diabetes, and the clas-
sification of the subjects as obese, all 
increased the risk of diabetic complica-
tions in the study cohort. To further in-
crease the progression of macrovascu-
lar complications, particularly the risk of 
cardiovascular events, the study cohort 
was not on any prophylactic cholesterol-
lowering agents, while only 16.1% were 
on aspirin. Also, 61.3% presented with 
hypertension and 48.3% presented 
with high total cholesterol levels. Thus, 
the treatment of hyperglycaemia alone, 
without other prophylactic measures, is 
not likely to succeed in decreasing long-
term complications of diabetes mellitus. 
In this study, the diabetic treatment 
comprised metformin combined with 
a basal insulin. UKPDS (1977–1999) 
demonstrated that only 50% of normal 
β-cell function remains by the time type 
2 diabetes is diagnosed, and that this 
function continues to deteriorate over 
time, despite treatment.15 Thus, com-
bination therapy becomes a safer and 
more convenient option by combining 
two agents with different modes of ac-
tion to produce a synergistic therapeutic 
effect. The metformin and insulin combi-
nation in this study cohort is logical, as 
insulin resistance is targeted directly.16 

























Figure 2. Mean glucose concentration vs. time, showing AUC 0-150 (shaded area) for each 
insulin type 
Metformin reduces FBG and PPG by 
stimulating glycolysis in peripheral tis-
sues, reducing hepatic gluconeogene-
sis and improving insulin resistance and 
sensitivity; whilst insulin suppresses the 
increased hepatic glucose production 
and lowers FBG concentrations.17 
However, in this study, the current 
treatment (HN, M or HL, each in com-
bination with metformin) was shown to 
be ineffective in controlling postprandial 
glycaemia with respect to the following 
parameters: mean two-hour postprandi-
al glucose concentration at 120 minutes 
and AUC glucose 0-150 minutes. 
All insulins are similar in their phar-
macodynamic profiles, but differ in 
their pharmacokinetics. As HN, M and 
HL are pharmacologically classified 
as human basal insulins, they conse-
quently showed similar effects on the 
postprandial glucodynamic parameters. 
This study found no statistically signifi-
cant differences in the mean postpran-
dial glucose concentrations among the 
three insulins groups, each in combina-
tion with metformin at each time point, 
namely 0, 30, 60, 90, 120 and 150 
minutes. 
However, on closer inspection, the 
postprandial glucose-lowering effect 
of the HN group was consistent with 
lower glucose concentration values 
from baseline, for all time intervals, for 
the AUC glucose 0-150 minutes, compared to 
the M and HL groups (not statistically 
significant). 
This variability of the insulin respon-
siveness may be attributed to the differ-
ent pharmacokinetic characteristics of 
insulin. Compared to the lente insulins 
(M and HL), the onset of action of neutral 
protamine hagedorn (NPH) insulin (HN) 
is quicker.15 The early peak of HN was 
confirmed by Bilo, who showed that, af-
ter the administration of NPH insulins, an 
earlier rise of plasma insulin levels was 
observed, compared to the gradual in-
crease of plasma insulin levels after the 
administration of zinc insulins.18 Hence 
the pharmacokinetic differences of the 
insulins resulted in the pharmacody-
namic differences seen in this study.
This largest postprandial glucose 
reduction (not statistically significant) in 
the HN group was also influenced by the 
better glycaemic control of the group on 
entry, compared to the M and HL groups 
(Table I). Although not statistically signif-
icant, the HN group presented with the 
youngest group, the highest glycaemic 
control on entry and showed the lowest 
risk for cardiovascular disease (highest 
HDL:LDL ratio) and renal impairment 
(lowest creatinine levels), compared to 
the M and HL groups.
In conclusion, the current treatment of 
the study cohort was reviewed, as both 
FBG and PPG were not controlled due 
to the progressively worsening hyper-
glycaemia of type 2 diabetes. The study 
cohort’s current treatment of combining 
oral medications with an intermediate to 
long-acting insulin as a twice-a-day or 
single-dose bedtime regimen, was logi-
cal, as it did aim to control overall gly-
caemia and weight gain. The rationale 
for the use of the study cohort’s current 
treatment is that insulin, by suppressing 
hepatic glucose output during the night, 
will control the fasting blood glucose, 
while the oral medication(s) continues 
to control postprandial glucose levels 
and glucose throughout the day. How-
ever, as discussed above, the study 
cohort’s glycaemia was uncontrolled. 
As diabetes mellitus is a progressive 
disease, treatment should be intensified 
as the disease progresses. Hence, in 
this study cohort, the current treatment 
should be reviewed to target the fasting 
and postprandial hyperglycaemia. 
Any further dosage adjustments of 
the basal insulin doses would not be 
any more beneficial than the current 
treatment in this study cohort. Rather, 
the effect of twice-a-day versus a single 
bedtime insulin dose on FBG or PPG 
levels should be investigated further. 
In addition, a further increase in the 
metformin doses needs to be evaluated, 
as impaired renal function and the de-
velopment of lactic acidosis should first 
be investigated in this study cohort. The 
substitution of metformin with other oral 
agents (e.g. α-glucosidase inhibitors, 
meglitinide or thiazolidinediones) may 
Original Research
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improve glycaemic control by targeting 
both FBG and PPG, but the extent of this 
control is limited by the decline in beta 
cell response, which is common as the 
disease progresses. Thus, as DM is a 
disease that progresses with age, the 
addition of other hypoglycaemic agents 
(i.e. short-acting insulins) that target 
postprandial hyperglycaemia to the 
current treatment would be most ben-
eficial and cost effective. The use of a 
combination of short/rapid-acting insulin 
with a newly-formulated basal/long-act-
ing insulin (such as insulin glargine) is 
recommended, as both FBG and PPG 
should be treated to achieve overall gly-
caemic control.
This study also showed that the 
extent of fasting hyperglycaemia de-
termines the degree of postprandial 
hyperglycaemia, and thus should be 
monitored. An approximation of PPG 
at one hour, as opposed to two hours, 
will not impact on the interpretation of 
glucose levels postprandially, as this 
study showed no statistically significant 
differences between PPG levels at 60, 
90 and 120 minutes. This would benefit 
busy clinical settings.
Evidence shows that targeting FBG 
is more beneficial when HbA1c and 
fructosamine values are very high, 
whereas targeting PPG is more effective 
when HbA1c and fructosamine values 
are lower.19 As FBG improves, the PPG 
contribution to glycaemic control domi-
nates, and when HbA1c values decrease 
to 7%, the PPG contribution increases 
to about 70%.19 This study therefore 
recommends that postprandial glucose 
measurements should have an equal 
place with fasting glucose measure-
ments in the management of type 2 DM 
to achieve overall glycaemic control and 
hence prevent diabetic complications. 
Disclosure: Neither author has any real 
or apparent conflict of interest to the 
content presented here.
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